methamphetamine (Rx)Brand and Other Names:Desoxyn

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet: Schedule II

  • 5mg
more...

Attention Deficit Hyperactivity Disorder

Initial: 5 mg PO qDay or q12hr; may increase daily dose at weekly intervals of 5 mg/day until optimal response

Maintenance: Usual effective dose is 20-25 mg/day; daily dose may be divided q12hr

Obesity, Short Term Treatment

5 mg PO q8hr, 30 minutes before each meal

Dosage Forms & Strengths

tablet: Schedule II

  • 5mg
more...

Attention Deficit Hyperactivity Disorder

<6 years: Safety and efficacy not established

≥6 years: 5 mg PO qDay or q12hr, may increase daily dose at weekly intervals of 5 mg/day until optimal response (ususally 20-25 mg/day)

Daily dose may be divided q12hr

Obesity

<12 years: Safety and efficacy not established

≥12 years: As adults; 5 mg PO q8hr 30 minutes before each meal

Next

Interactions

Interaction Checker

methamphetamine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Common

            • Hypertension, palpitations, tachyarrhythmia
            • Dizziness, drug tolerance, dysphoric mood, euphoria, headache, insomnia, restlessness, tremor
            • Urticaria
            • Constipation, diarrhea, taste sense altered, xerostomia

            Serious

            • Cardiorespiratory arrest, sudden death (rare), myocardial infarction
            • Cerebrovascular accident, Gilles de la Tourette's syndrome, seizure, psychotic disorder
            • Also see sympathomimetic syndrome, amphetamine toxicity
            • Musculoskeletal: Rhabdomyolysis
            Previous
            Next

            Warnings

            Black Box Warnings

            Amphetamine has a high potential for abuse. Particular attention should be paid to the possibility of patients obtaining amphetamine for nontherapeutic use or distribution to others, and the drugs should be prescribed or dispensed sparingly

            Administration of amphetamine for prolonged periods of time may lead to drug dependence and must be avoided

            Use therapy in weight reduction programs when alternative therapy has been ineffective

            Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events

            Contraindications

            Within 14 days of MAOIs

            Advanced arteriosclerosis

            Symptomatic cardiovascular disease

            Hyperthyroidism

            Moderate-severe hypertension

            Hypersensitivity to sympathomimetic amines

            Glaucoma

            Agitated state

            History of drug abuse

            Patients with ADHD concomitant with Tourette's syndrome

            Breastfeeding

            Cautions

            Bipolar disorder, mild hypertension, history of seizures, diabetes (insulin requirement may be altered), history of aggressive behavior

            Do not give at late evening; may cause insomnia

            May impair ability to drive and/or operate heavy machinery

            Alkaline urine will significantly increase half-life

            Stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon

            Sudden deaths, stroke, and myocardial infarction reported in adults taking stimulants at usual doses

            Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation

            Particular care should be taken in using stimulants to treat ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episode in such patients

            Aggressive behavior or hostility is often observed in children and adolescents with ADHD; monitor for the appearance of or worsening of aggressive behavior or hostility

            Monitor growth of children ages 7 to 10 years during treatment with stimulants; may need to interrupt therapy in patients not growing or gaining weight as expected

            Stimulants may lower convulsive threshold in patients with prior history of seizure, patients with prior EEG abnormalities in absence of seizures, and very rarely, patients without a history of seizures and no prior EEG evidence of seizures; discontinue therapy in the presence of seizures

            Use with caution in patients who use other sympathomimetic drugs

            Amphetamines may exacerbate motor and phonic tics and Tourette’s syndrome; perform clinical evaluation for tics and Tourette’s syndrome in children and their families prior to treating with stimulant medications

            High abuse potential

            Rare instances of prolonged and sometimes painful erections (priapism), sometimes requiring surgical intervention, reported with methylphenidate products; typically not reported during initiation, but often subsequent to an increase in dose; seek immediate medical attention for abnormally sustained or frequent and painful erections

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Amphetamine anorexigenic agent; sympathomimetic amine related to ephedrine and amphetamine with CNS stimulant activity; causes release of dopamine and other catechoamines from their storage in the presynaptic nerve terminals; inhibits monoamine transporters and oxidase, causing reuptake and metabolism of catecholamines

            Pharmacokinetics

            Half-Life: 4-5 hr

            Absorption: Rapid

            Metabolism: Liver

            Excretion: Urine, varies with pH

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.